UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients With Refractory Hypoxia

Inclusion Criteria: The age ranges from 18 to85 (inclusive), regardless of gender. Patients who still have refractory hypoxia after sufficient standard treatment for severe and critical COVID-19 pneumonia following the suggestion of the Chinese diagnostic criteria for COVID-19 pneumonia in the Diagnosis and Treatment Plan for COVID-19 Pneumonia (Tentative tenth Edition). 20kg/m2≤body mass index(BMI)≤30 kg/m2. Volunteer to participate in this clinical study and sign the written informed consent Exclusion Criteria: Those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation. T lymphocyte abnormality (allogeneic may be considered, depending on clinical opinion), HIV positive. Highly allergic or have a history of severe allergy, especially Interleukin-2 allergy. Pregnant and lactating women. Patients with severe autoimmune disease history; Allergies to all biological reagents in this treatment, such as Interleukin-2. Patients with serious complications, including chronic cardiac insufficiency (NYHA cardiac function grading assessment of cardiac function grade III - IV), chronic renal insufficiency (CKD stage 3 and above); Chronic liver insufficiency (Child-Pugh score>7); Patients with malignant tumors. Patients with pulmonary embolism or acute coronary syndrome. Patients with severe organ dysfunction caused by other diseases. There are other situations that the researcher thinks are not suitable to participate in this clinical study